# Efficacy of Phosphodiesterase-type 5 Inhibitors in Patients With Univentricular Congenital Heart Disease

> **NCT03997097** · PHASE3 · WITHDRAWN · sponsor: **University Hospital, Montpellier**

## Conditions studied

- Single-ventricle
- Pulmonary Hypertension
- Univentricular Heart

## Interventions

- **DRUG:** Sildenafil
- **DRUG:** Placebos

## Key facts

- **NCT ID:** NCT03997097
- **Lead sponsor:** University Hospital, Montpellier
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-06-01
- **Primary completion:** 2026-06-01
- **Final completion:** 2028-06-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** New sponsor
- **Last updated:** 2023-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03997097

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03997097, "Efficacy of Phosphodiesterase-type 5 Inhibitors in Patients With Univentricular Congenital Heart Disease". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03997097. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*